BMA vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a bullish analyst recommendation and strong long-term price appreciation, the company faces deteriorating fundamentals, including negative operating margins, a steep decline in year-over-year revenue and earnings, and extremely stretched valuation metrics. The stock trades at a massive premium to both the Graham Number ($17.18) and intrinsic value estimate ($17.64), with a current price of $96.63, suggesting substantial overvaluation. While dividend yield and recent technical rebound offer some support, the underlying financial deterioration and lack of transparency in key leverage and liquidity metrics amplify downside risk.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BMA vs JPM: Head-to-Head Comparison
This page compares Banco Macro S.A. (BMA) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.